




The relative strengths and weaknesses of Sonoma Pharmaceuticals Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Sonoma Pharmaceuticals Inc compared to the market average is the variable Liabilities, increasing the Economic Capital Ratio by 123% points. The greatest weakness of Sonoma Pharmaceuticals Inc is the variable Selling, General and Administrative Expense, reducing the Economic Capital Ratio by 70% points.

The company's Economic Capital Ratio, given in the ranking table, is 279%, being 29% points above the market average of 250%.

Input Variable	Value in 1000 USD
Assets, Current	16,254
Cost of Goods Sold	9,348
Intangible Assets	0
Liabilities, Current	3,261
Liabilities, Non-Current	32
Other Assets	1,816
Other Compr. Net Income	0
Other Expenses	90
Other Liabilities	587
Other Net Income	-49
Other Revenues	16,658
Property and Equipment	1,136
Research and Development	1,575
Selling, General and Administrative Expense	19,924

Output Variable	Value in 1000 USD
Assets	19,206
Liabilities	3,880
Expenses	30,937
Revenues	16,658
Stockholders Equity	15,326
Net Income	-14,328
Comprehensive Net Income	-14,328
BaseVar	35,365
ECR before Limited Liability	165%
Economic Capital Ratio	279%